Angle Share Discussion Threads

[havinthelasttoast] 02/7/2024 12:57

Are we all ready for the dump ?

[fhmktg] 02/7/2024 07:23

Thanks Bermuda
As well as reaching other drug developers, could this work lead to an LDT ?

[millwallfan] 01/7/2024 17:22

Hopefully we can look forward to some steady progress during the remainder of this calendar year !

[countbasie1] 01/7/2024 17:12

BermudashortsThanks for posting.

[bermudashorts] 01/7/2024 16:47

The second poster is reporting on Angles recently launched DDR assays. These assays were originally developed for Artios Pharma and Angle have also recently signed a contract with AstraZeneca for development of another DDR assay.

The section of the poster looking at patient results (ovarian and prostate) is particularly interesting and definitely worth a read for longs here.

' This study demonstrated the possibility of using the DDR workflow to monitor the number of CTCs and DDR+ CTCs over time. Applied to a clinical setting, this workflow can potentially allow for minimally invasive monitoring of DNA damage targeting therapies'

[bermudashorts] 01/7/2024 16:47

Not sure whether this has already been discussed but Angle have now uploaded to their website two posters recently presented at EACR in Rotterdam. The first details further research on concurrent analysis of both CTCs and ctDNA from the same blood draw.

The study looked at ovarian, breast and lung cancer patients and found the same mutations present on both CTCs and ctDNA in 61%, 30% and 34% of samples respectively. However, when looking at mutations found from one source alone (either only from CTCs or only from ctDNA)they found for all 3 cancer types that higher percentages of mutations were found only on CTCs compared to ctDNA (32%, 46% & 46%). Angle say this demonstrates that concurrent analysis of both CTCs and ctDNA provides complimentary data. Their conclusion:-

'The added value of CTC profiling using the Parsortix system is its ability to capture a comprehensive picture of the tumour's genetic heterogeneity. By interrogating both CTCs and cfDNA in parallel, this integrated approach holds promise for potentially guiding personalized cancer treatment selection, monitoring therapeutic responses, and improving overall clinical management strategies for patients.'

[sawney] 01/7/2024 08:22

Miavoce...

Thank you...

[miavoce] 30/6/2024 20:05

part - increasing revenue would put the cash raise further out. If they achieve the £5m in H2 this will give them about another 3 months. So, if a further raise is needed, it will probably be end 1Q2025.

[purchaseatthetop] 30/6/2024 13:33

Havinthelasttoast.
Not $2m a month. Around $1.25m a month. Will be higher if R@D credits of $3m odd not received in future.
Savings are not easy to deliver in times of inflation and when they are trying to grow so I would put much hope there.
$24m year end cash plus cash raise will be about $16m now. They will need to raise early 2025.

[bagpuss67] 30/6/2024 12:14

Toasty. Did you look at the cashflow statement in the FY23 accounts?

Let's start with that and please demonstrate how that takes you to £2m pm..

[havinthelasttoast] 30/6/2024 11:52

Nop. Well documented 2m per month cash burn rate.

[miavoce] 30/6/2024 09:06

For contrast, the view of BigBiteNow on the other site.

I really don't understand what this £2m cash burn per month is being built from other than a desire to paint a bad picture.

In 2023 AGL actual FY cash burn was c. £16m. That's equal to £1.33m cash burn per month.

But the YE end cash position was £16.2m vs. £22.2m on 30th June indicating a cash burn in H2 2023 of c. £6m which is £1,000,000 per month.

In addition further cost savings are expected in 2024.

"The streamlining is expected to deliver cost savings of c. £3 million per annum in 2024 resulting in the extension of the cash runway into Q2 2025."

They are worth up to £250k per month. They may not achieve all of them, but any further improvement is a positive for that cash burn.

Then we have increasing revenues. H2 cash burn was achieved against just £1m in revenues. So far this year revenues are reportedly running at c. £2.6m with more to come. Again they may not reach their £6.45m goal but they are already ahead of last year with c. 6 months more still to go.

This will also help lower monthly cash burn.

Nowhere is any of the available information is there evidence that AGL is burning anywhere near £2m a month.

YE cash was £16.2m + £8.77m raised = c. £25m minus placing costs.

On the above evidence, AGL has at least 12 months before any questions need to be raised over further funding and it is fair to expect that multiple deals will be landing in that timescale.

[bagpuss67] 30/6/2024 09:02

PwC said. "Going concern was identified as an area of significant risk and therefore required significant attention and audit effort by us during the audit including consideration of the accuracy of management’s forecasts and ability to control the underlying cost base of the business."

GC is a big deal for auditors and they have spent quite a bit of time on it and NOT concluded that there is material uncertainty in AGL having enough cash to trade into mid 2025. That's the best info we have at the moment.

[havinthelasttoast] 28/6/2024 13:19

You are not on this dog also count hahah

I warned all the mugs here also the same as bluejay. You do know how to pick a dog count. I’m going to start the countbasie inverted etf, it will be huge.

In the meantime what comes after a pump. They are going to dump this hard. Don’t be fooled

[countbasie1] 28/6/2024 12:16

Bants hotting up here nicely

[5oletrader] 28/6/2024 10:36

@BshortsHttps://www.guysandstthomasbrc.nihr.ac.uk/wp-content/uploads/2018/10/BRC-Flo-web-002.pdf

[bermudashorts] 28/6/2024 10:00

Good to see Parsortix listed amongst the standard equipment in this job advert from Guy's and St Thomas' for research technicians:-

'We maintain 15 analysers and sorters, including those from Beckman, BD and Cytek, as well as Luminex, ImageStream, Parsortix, Helios and Hyperion.'

'We support over 400 users and 100 laboratories from various backgrounds. Goals including immune monitoring, biomarker discovery and assay development for personalised medicine and drug discovery. We have pipelines into cell sequencing and therapeutic products.'

[sawney] 28/6/2024 09:25

They've clearly got enough for 12+ months....next...

[spa362] 27/6/2024 18:28

I am thinking that the share price will be mostly up over the next little while

[ohwhatfun] 27/6/2024 14:08

If AGL had bitten the bullet, last fund raise, securing the amount they needed, then it would all be very exciting, new investors would be buying gambling on good fortune ahead.

Sadly they didn’t, and hence they have created a potential opening for the money market to kick them in the teeth, short term.

That said even with a revenue missed raise for £8-£10m at 8p it still balances out at 11-12p average for the whole raise.

But for a break even plan on a monthly basis end of 2025, considerably more than the typical cash burn rate will be needed, which means a higher fund raise amount.

Not that new investors will be moaning too much at £2m a month revenue or more in 18 months.

It stills sounds like a tall order at 10 times the last 6 months rate.

[htrocka2] 27/6/2024 09:32

'Delivery of the test results to Eisai..'


rns extract
'Success in the pilot study offers the potential for multiple large scale follow-up studies.'

Let's see how Eisai get on with Phase 11. This could be an important milestone.